{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:50:03Z","timestamp":1789181403002,"version":"build-2803163510"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.coi.2026.102805","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:33:54Z","timestamp":1782146034000},"page":"102805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Reconsidering the immunological aspects of solid-phase assays for antiphospholipid antibodies detection"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8967-9678","authenticated-orcid":false,"given":"Maria Orietta","family":"Borghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3330-138X","authenticated-orcid":false,"given":"Elena","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2718","authenticated-orcid":false,"given":"Caterina","family":"Bodio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0796-7535","authenticated-orcid":false,"given":"Arianna","family":"Da Via","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7559-2579","authenticated-orcid":false,"given":"Katrien MJ","family":"Devreese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102805_bib1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102805_bib2","doi-asserted-by":"crossref","first-page":"SI4","DOI":"10.1093\/rheumatology\/kead603","article-title":"Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones?","volume":"63","author":"Raschi","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102805_bib3","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood.V84.9.2854.2854","article-title":"Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other \"antiphospholipid\" autoantibodies","volume":"84","author":"Roubey","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102805_bib4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/1744666X.2019.1546578","article-title":"Pathogenesis of antiphospholipid syndrome: recent insights and emerging concepts","volume":"15","author":"Lackner","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.coi.2026.102805_bib5","series-title":"Manual of Molecular and Clinical Laboratory Immunology","article-title":"Antiphospholipid antibody syndrome","author":"Meroni","year":"2024"},{"key":"10.1016\/j.coi.2026.102805_sbref6","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2024.110282","article-title":"Domain 5 of beta 2 glycoprotein I: friend or foe in health? Context matters","volume":"265","author":"Giannakopoulos","year":"2024","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coi.2026.102805_bib7","article-title":"Understanding the structure of \u03b22-glycoprotein I: new insights and future paths for antiphospholipid syndrome","volume":"2","author":"Kumar","year":"2024","journal-title":"Blood Vessel Thromb Hemost"},{"key":"10.1016\/j.coi.2026.102805_sbref8","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood.2025029488","article-title":"Domain and residue mapping of autoantibodies to \u03b22GPI reveals differences among antiphospholipid syndrome phenotypes","volume":"146","author":"Kumar","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102805_sbref9","article-title":"The J-shape of \u03b22GPI reveals a cryptic discontinuous epitope across domains I and II","volume":"12","author":"Lalaurie","year":"2025","journal-title":"J Struct Biol X"},{"key":"10.1016\/j.coi.2026.102805_bib10","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2009-12-260976","article-title":"Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome","volume":"116","author":"Agar","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102805_bib11","doi-asserted-by":"crossref","first-page":"5732","DOI":"10.4049\/jimmunol.157.12.5732","article-title":"The anti-beta2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native beta2-glycoprotein I and preserved during species' evolution","volume":"157","author":"Tincani","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2026.102805_bib12","doi-asserted-by":"crossref","first-page":"10794","DOI":"10.1074\/jbc.RA120.013939","article-title":"The J-elongated conformation of \u03b22-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome","volume":"295","author":"Ruben","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coi.2026.102805_bib13","first-page":"1684","article-title":"Beta 2 glycoprotein I and placental anticoagulant protein I in placentae from patients with antiphospholipid syndrome","volume":"21","author":"Rosa","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2026.102805_bib14","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1182\/blood-2011-01-333617","article-title":"In vivo distribution of \u03b22 glycoprotein I under various pathophysiologic conditions","volume":"118","author":"Agostinis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102805_bib15","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/keaa203","article-title":"EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodies","volume":"60","author":"Pregnolato","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102805_bib16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1586\/17474086.2016.1140034","article-title":"The challenges of lupus anticoagulants","volume":"9","author":"Chighizola","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.coi.2026.102805_bib17","doi-asserted-by":"crossref","first-page":"102784","DOI":"10.1016\/j.coi.2026.102784","article-title":"The role of different aPL subpopulations in the lupus anticoagulant phenomenon","volume":"100","author":"Arachchillage","year":"2026","journal-title":"Cur Opin Immunol"},{"key":"10.1016\/j.coi.2026.102805_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.726820","article-title":"Antiphospholipid antibody assays in 2021: looking for a predictive value in addition to a diagnostic one","volume":"12","author":"Meroni","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102805_bib19","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1055\/s-0037-1603936","article-title":"Prevalence and thrombotic risk assessment of anti-\u03b22 glycoprotein I domain I antibodies: a systematic review","volume":"44","author":"Radin","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.coi.2026.102805_bib20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1182\/blood.V61.4.684.684","article-title":"A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome","volume":"61","author":"Bajaj","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102805_bib21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1182\/blood.V72.2.512.512","article-title":"Anti-prothrombin antibodies and the lupus anticoagulant","volume":"72","author":"Fleck","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102805_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1055\/s-0038-1646476","article-title":"Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin","volume":"66","author":"Bevers","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib23","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/bloodadvances.2019030932","article-title":"Discovery and characterization of 2 novel subpopulations of aPS\/PT antibodies in patients at high risk of thrombosis","volume":"3","author":"Chinnaraj","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2026.102805_bib24","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1016\/j.jtha.2024.07.005","article-title":"Understanding the difference between type I and type II antiprothrombin antibodies and their effect on activated protein C resistance","volume":"22","author":"Pozzi","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_sbref25","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.jtha.2025.03.029","article-title":"Lupus anticoagulant and antiprothrombin antibodies: embracing the future","volume":"23","author":"Pengo","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1160\/TH13-06-0509","article-title":"Anti-prothrombin (aPT) and anti-phosphatidylserine\/prothrombin (aPS\/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review","volume":"111","author":"Sciascia","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2022.04.021","article-title":"Prevalence of aPhosphatidylserine\/prothrombin antibodies and association with antiphospholipid antibody profiles in patients with antiphospholipid syndrome: a systematic review and meta-analysis","volume":"214","author":"Zhu","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.coi.2026.102805_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13621","article-title":"Antiphosphatidylserine\/prothrombin antibodies (aPS\/PT) and risk of obstetric anti-phospholipid syndrome","volume":"89","author":"Zhang","year":"2023","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.coi.2026.102805_bib29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1055\/s-0040-1705115","article-title":"Antiphosphatidylserine\/prothrombin antibodies: an update on their association with clinical manifestations of antiphospholipid syndrome","volume":"120","author":"Radin","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1515\/cclm-2017-0502","article-title":"Antiphosphatidylserine\/prothrombin antibodies (aPS\/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome","volume":"56","author":"Shi","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.coi.2026.102805_sbref31","first-page":"55","article-title":"Association between novel antiphospholipid antibodies and adverse pregnancy outcomes","volume":"145","author":"Moyle","year":"2025","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.coi.2026.102805_bib32","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/jth.14765","article-title":"Tetra positive thrombotic antiphospholipid syndrome: major contribution of anti-phosphatidyl-serine\/prothrombin antibodies to lupus anticoagulant activity","volume":"18","author":"Cattini","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib33","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1111\/jth.15792","article-title":"Anti-phosphatidylserine prothrombin antibodies as a predictor of the lupus anticoagulant in an all-comer population","volume":"20","author":"Pham","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib34","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1111\/jth.15785","article-title":"Added value of antiphosphatidylserine\/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: communication from the ISTH SSC subcommittee on lupus anticoagulant\/antiphospholipid antibodies","volume":"20","author":"Vandevelde","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib35","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/keab414","article-title":"Non-criteria antiphospholipid antibodies': bridging the gap between seropositive and seronegative antiphospholipid syndrome","volume":"61","author":"Truglia","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102805_bib36","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/jth.15455","article-title":"Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19","volume":"19","author":"Hollerbach","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib37","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1111\/jth.13865","article-title":"Antiphospholipid antibody-induced cellular responses depend on epitope specificity: implications for treatment of antiphospholipid syndrome","volume":"15","author":"M\u00fcller-Calleja","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib38","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/10408363.2024.2305121","article-title":"Lipid-binding antiphospholipid antibodies: significance for pathophysiology and diagnosis of the antiphospholipid syndrome","volume":"61","author":"M\u00fcller-Calleja","year":"2024","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.coi.2026.102805_bib39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.thromres.2004.06.032","article-title":"An adapted ELISA method for differentiating pathogenic from nonpatho\u00acgenic aPL by beta 2 glycoprotein dependency anticar\u00acdiolipin assay","volume":"114","author":"Levy","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.coi.2026.102805_bib40","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.exger.2004.08.003","article-title":"Anti-beta 2 glycoprotein I antibodies in centenarians","volume":"39","author":"Meroni","year":"2004","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.coi.2026.102805_bib41","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2014.10.013","article-title":"Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant","volume":"135","author":"Pengo","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.coi.2026.102805_bib42","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1055\/a-1344-4271","article-title":"Clinical relevance of isolated lupus anticoagulant positivity in patients with thrombotic antiphospholipid syndrome","volume":"121","author":"Yin","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib43","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1006\/bbrc.1994.2394","article-title":"Heterogeneity and diversity of IgM and IgG lupus anticoagulants in an individual with system lupus erythematosus","volume":"203","author":"Nakamura","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.coi.2026.102805_bib44","first-page":"102","article-title":"Characterization of IgG monoclonal anti-cardiolipin\/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies","volume":"105","author":"Zhu","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.coi.2026.102805_bib45","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood-2004-03-1107","article-title":"\u03b22-glycoprotein I dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome","volume":"104","author":"de Laat","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102805_bib46","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1055\/s-0037-1606190","article-title":"The lupus anticoagulant paradox","volume":"44","author":"Molhoek","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.coi.2026.102805_bib47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1006\/jaut.1999.0316","article-title":"Isolation and characterization of two human monoclonal anti-phospholipid IgG from patients with autoimmune disease","volume":"13","author":"von Landenberg","year":"1999","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2026.102805_bib48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1055\/s-0037-1613867","article-title":"Analysis of prothrombotic effects of two human monoclonal IgG antiphospholipid antibodies of apparently similar specificity","volume":"83","author":"Lackner","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib49","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood-2011-01-330639","article-title":"Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells","volume":"118","author":"Prinz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102805_bib50","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.2019001530","article-title":"Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis","volume":"134","author":"M\u00fcller-Calleja","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102805_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc0956","article-title":"Lipid presentation by the protein C receptor links coagulation with autoimmunity","volume":"371","author":"M\u00fcller-Calleja","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.coi.2026.102805_bib52","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1055\/s-0039-1685453","article-title":"Platelet activation by antiphospholipid antibodies depends on epitope specificity and is prevented by mTOR inhibitors","volume":"119","author":"Hollerbach","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib53","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1055\/a-2510-6147","article-title":"Association of specific antiphospholipid antibodies to platelet count and thrombocytopenia","volume":"125","author":"Griem","year":"2025","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib54","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/jth.13263","article-title":"Cofactor-independent human antiphospholipid antibodies induce venous thrombosis in mice","volume":"14","author":"Manukyan","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-0897.1998.tb00344.x","article-title":"The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome","volume":"39","author":"Rote","year":"1998","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.coi.2026.102805_bib56","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/annrheumdis-2016-210012","article-title":"Hydroxychloroquine inhibits proinflammatory signal\u00acling pathways by targeting endosomal NADPH oxidase","volume":"76","author":"M\u00fcller-Calleja","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102805_bib57","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/bloodadvances.2018017095","article-title":"Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphos\u00acpholipid antibodies","volume":"2","author":"M\u00fcller-Calleja","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2026.102805_bib58","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.autrev.2018.12.006","article-title":"The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 1000 consecutive cases","volume":"18","author":"Alijotas-Reig","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102805_bib59","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/acr.24468","article-title":"Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION International Clinical Database and Repository","volume":"74","author":"Sevim","year":"2022","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.coi.2026.102805_bib60","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","article-title":"Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature","volume":"101","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102805_bib61","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1182\/blood-2002-11-3334","article-title":"Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome","volume":"102","author":"Galli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.coi.2026.102805_bib62","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.autrev.2013.11.004","article-title":"Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis","volume":"13","author":"Reynaud","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2026.102805_bib63","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/bloodadvances.2021005205","article-title":"A systematic review of the association between anti-\u03b2-2 glycoprotein I antibodies and APS manifestations","volume":"5","author":"Jiang","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2026.102805_bib64","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/annrheumdis-2021-220206","article-title":"Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients","volume":"80","author":"Trahtemberg","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102805_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.930074","article-title":"Anti-phospholipid antibodies and coronavirus disease 2019: vaccination does not trigger early autoantibody production in healthcare workers","volume":"13","author":"Borghi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102805_bib66","doi-asserted-by":"crossref","DOI":"10.1186\/ar4549","article-title":"Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers","volume":"16","author":"Meroni","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.coi.2026.102805_bib67","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1018-x","article-title":"Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers","volume":"18","author":"Roggenbuck","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.coi.2026.102805_sbref68","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ijlh.14268","article-title":"Noncriteria antiphospholipid antibodies in antiphospholipid syndrome","volume":"46","author":"Devreese","year":"2024","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.coi.2026.102805_sbref69","first-page":"73","article-title":"An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"23","author":"Devreese","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_sbref70","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jtha.2024.09.021","volume":"23","author":"Meroni","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2026.102805_bib71","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41584-018-0032-6","article-title":"Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?","volume":"14","author":"Meroni","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2026.102805_bib72","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaut.2018.07.002","article-title":"Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome","volume":"93","author":"Ripoll","year":"2018","journal-title":"J Autoimmun"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:39:23Z","timestamp":1783931963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526000828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":72,"alternative-id":["S0952791526000828"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102805","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reconsidering the immunological aspects of solid-phase assays for antiphospholipid antibodies detection","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102805"}}